Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Coupe

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Rheumatology (Oxford, England)|December 10, 2019
Toxicities associated with checkpoint inhibitors-an overviewLaura Spiers, Nicholas Coupe, Miranda Payne
British Journal of Hospital Medicine (London, England : 2005)|July 4, 2015
Early phase cancer clinical trials: design, ethics and future directionsNicholas Coupe, Avinash Gupta, Simon R Lord
Clinical Endocrinology|March 25, 2026
Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and RecoveryShani A D Mathara Diddhenipothage, Jacqui Warden, Katie Herbert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelNicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 20, 2022
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanomaNicholas Coupe, Lina Guo, Esther Bridges, et al.
Cancers|January 10, 2026
Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational ExperienceUmair Mahmood, Eleni Josephides, Nicholas Coupe, et al.
Cancers|September 13, 2025
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre StudyUmair Mahmood, Eleni Josephides, Meenali Chitnis, et al.
Cancer|October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancerToby A Eyre, Graham P Collins, Avinash Gupta, et al.
British Journal of Cancer|March 16, 2021
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profilesWeiyu Ye, Anna Olsson-Brown, Robert A Watson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2020
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older PatientsMitchell E Fane, Brett L Ecker, Amanpreet Kaur, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Rheumatology (Oxford, England)|December 10, 2019
Toxicities associated with checkpoint inhibitors-an overviewLaura Spiers, Nicholas Coupe, Miranda Payne
British Journal of Hospital Medicine (London, England : 2005)|July 4, 2015
Early phase cancer clinical trials: design, ethics and future directionsNicholas Coupe, Avinash Gupta, Simon R Lord
Clinical Endocrinology|March 25, 2026
Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and RecoveryShani A D Mathara Diddhenipothage, Jacqui Warden, Katie Herbert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelNicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 20, 2022
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanomaNicholas Coupe, Lina Guo, Esther Bridges, et al.
Cancers|January 10, 2026
Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational ExperienceUmair Mahmood, Eleni Josephides, Nicholas Coupe, et al.
Cancers|September 13, 2025
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre StudyUmair Mahmood, Eleni Josephides, Meenali Chitnis, et al.
Cancer|October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancerToby A Eyre, Graham P Collins, Avinash Gupta, et al.
British Journal of Cancer|March 16, 2021
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profilesWeiyu Ye, Anna Olsson-Brown, Robert A Watson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2020
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older PatientsMitchell E Fane, Brett L Ecker, Amanpreet Kaur, et al.
Pageof 2